Talal Bachir Chamseldin Seddik, MD
Pediatric Infectious Diseases · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Seddik’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A136576 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · University of Cairo Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Infectious Diseases
- American Board of Pediatrics - Pediatrics
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2025 | Their institution | $151,887 |
| Merck Sharp & Dohme LLC · A Phase 1, Open-Label, Single-Arm Study To Evaluate the Pharmacokinetics and Safety of Letermovir in Pediatric Kidney Transplant Kt Recipients Less Than 18 Years of Age and Weighing Less Than 40 Kilograms · 2025 | Their institution | $103,851 |
| PFIZER INC. · A Phase 2 Randomized Doubleblind Trial To Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants · 2025 | Their institution | $37,826 |
| PFIZER INC. · A Phase 12 Randomized Observerblind Study To Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals · 2025 | Their institution | $7,848 |
| PFIZER INC. · A Phase 3 Protocol To Investigate the Safety Tolerability and Immunogenicity of A Bnt162b2 Lp81adapted Vaccine in Children 5 Through 11 Years of Age Considered at High Risk for Severe Covid19 · 2025 | Their institution | $1,944 |
| SANOFI PASTEUR INC. · A Phase 3, Randomized, Modified Double-Blind, Active-Controlled, Parallel-Group, 2arm Study To Investigate the Safety of A 4-Dose Regimen of A 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers · 2024 | This clinician | $1,784 |
| SANOFI US SERVICES INC. · A Phase 3, Randomized, Modified Double-Blind, Active-Controlled, Parallel-Group, 2arm Study To Investigate the Safety of A 4-Dose Regimen of A 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers · 2024 | This clinician | $96 |
Professional record
- NPI
- 1922449636
- Licence
- CA A136576, FL TRN 17781California A136576: Current · expires 2027-04-30
More record details
- Sole proprietor
- No
- Medicaid ID
- FL 1922449636
- Taxonomy
- Federal specialty code 2080P0208X (2080P0208X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2013-07-10
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5153 N 9th Ave, Pensacola, FL, 32504 · 300 Pasteur Dr Rm 312, Stanford, CA, 94305